ArticleFrontiers in medicine2025
Non-invasive assessment of liver fibrosis staging in chronic hepatitis B patients: combining two-dimensional shear wave elastography with serum indicators.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Use of Ultrasound-Based Elastography Techniques in Liver Fibrosis: A Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to evaluate the diagnostic accuracy of a novel approach that combines noninvasive indicators with two-dimensional shear wave elastography (2D SWE) to assess liver fibrosis stages in patients with chronic hepatitis B (CHB), using the Scheuer score as the reference standard. Methods and materials: 2D SWE and serum indicators are commonly used for the noninvasive assessment of liver fibrosis. A total of 102 patients with CHB underwent 2D SWE measurements and serum tests for liver fibrosis markers. Standardized protocols were followed for all diagnostic procedures to ensure reproducibility and consistency. Binary logistic regression was used to generate a combined predictive probability value. Receiver operating characteristic (ROC) curves were used to evaluate the efficacy of the noninvasive diagnosis of liver fibrosis stages. Results: Combining multiple serum indicators increased the AUC for diagnosing substantial liver fibrosis from 0.735 (0.650-0.810) to 0.825 (0.746-0.888) ( Conclusion: The combination of multiple noninvasive indicators can improve the accuracy of assessing liver fibrosis stages in patients with CHB. This approach offers a potential noninvasive alternative to liver biopsy for assessing liver fibrosis, particularly in advanced stages that require clinical intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.